The Effect of Cognitive Functions on Upper Extremity Functionality in Parkinson's Patients
Study Overview
Status
Intervention / Treatment
Detailed Description
Parkinson's Disease (PD), first described by James Parkinson in 1817, is a progressive movement disorder that develops mainly as a result of the destruction of nigrostriatal dopaminergic neurons. Involvement of nigrostriatal dopaminergic neurons is associated with the motor manifestations of the disease. The most common of these symptoms are; resting tremor, bradykinesia, rigidity and balance disorder. However, non-motor symptoms related to the involvement of nervous system structures other than the dopaminergic nigrostriatal system can be observed in PD. However, due to the predominance of motor symptoms in PD, it took many years to notice cognitive changes. Traditionally, cognitive impairments in PD have been expected to occur in the advanced stages of the disease. However, cognitive impairments in the early stages are reported in approximately 30-35% of patients. Cognitive dysfunction is defined in PD, ranging from mild impairments in certain cognitive domains to severe dementia. Cognitive impairment primarily affects executive and visuospatial functions, and memory is secondarily affected.
Executive functions are higher cognitive processes that use and modify information from many cortical sensory systems in the fore and hindbrain areas to modulate and teach behavior. The frontal cortex, especially the prefrontal cortex and its striatal connections are very important neuroanatomical regions for executive functions. The relationship between the effects of cognition and motor performance and parameters in groups such as the elderly, PD and Alzheimer's patients in which these centers are affected has been an issue that has attracted the attention of many researchers. Most of the studies have focused on the lower extremity performance of cognition. However , it has been reported that cognition has positive effects on upper extremity performance and early acquired upper extremity skills have positive effects on cognitive performance .
The aim of our study is to determine the effect of cognitive functions on upper extremity functionality in individuals with Parkinson's Disease.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Denizli, Turkey, 20000
- Pamukkale Unıversity
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Having a diagnosis of Parkinson's Disease.
- Not having hearing and vision problems.
- To be able to take the commands required for the manual dexterity tests.
- Agree to participate in the study.
Exclusion Criteria:
- Having undergone musculoskeletal surgery for the upper extremity.
- Having vision and hearing problems.
- Having an additional disease that may affect cognitive tests.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: patient group
parkınson patient group
|
clinical staging
Other Names:
|
|
Other: healthy group
age-gender matched healthy group
|
clinical staging
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Modified Hoehn Yahr Scale
Time Frame: 1 year
|
Used for clinical staging of Parkinson's disease
|
1 year
|
|
Unified Parkinson's Disease Rating Scale
Time Frame: 1 year
|
Used for the evaluation of clinical manifestations of Parkinson's disease
|
1 year
|
|
Parkinson's Disease Questionnaire-PDQ 39
Time Frame: 1 year
|
Used to assess the quality of life of Parkinson's patients
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Stroop Test
Time Frame: 1 year
|
measures the selective attention ability of individuals
|
1 year
|
|
Wechsler Memory Scale-Revised
Time Frame: 1 year
|
To assess attention, learning, memory and working memory in individuals aged 16-89
|
1 year
|
|
Dexterity Questionnaire-24
Time Frame: 1 year
|
To assess manuel dexterity
|
1 year
|
|
Nine Hole Peg Test
Time Frame: 1 year
|
To assess manuel dexterity
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: DUDU ŞIMŞEK, PhD student
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PamukkaleU-sımsek-parkınson-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.